How emerging biotechs can enter the Chinese market and prosper
In this article, Parexel experts outline five approaches that foreign companies with limited resources should use to gain a foothold in the Chinese market.
Read More
In this article, Parexel experts outline five approaches that foreign companies with limited resources should use to gain a foothold in the Chinese market.
Read More
Article from December 2021 edition of Applied Clinical Trials. Parexel regulatory experts offer top tips for working with regulators on a global scale.
Read More
Error - something went wrong!
Let's start a conversation...
Thank you! We'll be in touch soon.
The FDA released a draft guidance that outlines regulatory considerations for INDs that study multiple versions of a cellular or gene therapy (CGT) product in a single trial. There are some...
Learn More
In this article, Regulatory expert, Cecil Nick, looks at the latest MHRA guidance and what the future holds for biosimilar development.
Learn More
Slides presented during virtual roundtable, entitled "Making expedited regulatory pathways work for global drug development programs"
Read More
Parexel Clinical Trial Regulatory Services consultants share what you should be doing now to prepare for the coming changes.
Read More
The science of ethnobridging – a way to implement cost-effective, multi-ethnic approaches to global clinical trial research and drug development.
Read More
Learn about the services and approaches that Parexel Biotech offers to help you make an exponential difference in patients’ lives.
Read More
Amy McKee, Vice President Regulatory Consulting Services, addresses some of the most common misconceptions about working with the FDA.
Learn More
The UK national health technology assessment (HTA) body, the National Institute for Health and Clinical Excellence (NICE), made a long-awaited announcement last week: NICE has expanded the...
Learn More
We have some tips for mapping your strategy
Learn More
It’s never too early to start crafting a global regulatory submissions strategy.
Read More